Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
Birmingham VA Medical Center, Birmingham, Alabama.
Kidney360. 2023 Sep 1;4(9):e1332-e1340. doi: 10.34067/KID.0000000000000221.
Gout, a common form of inflammatory arthritis, is characterized by deposition of monosodium urate crystals in articular and periarticular tissues. Repeated flares of gout cause joint damage as well as significant health care utilization and decreased quality of life. Patients with CKD have a higher prevalence of gout. Treating Patients with CKD and gout is challenging because of the lack of quality data to guide management in this specific population. This often leads to suboptimal treatment of patients with gout and impaired renal function because concerns regarding the efficacy and safety of available gout therapies in this population often result in significant interphysician variability in treatment regimens and dosages. Acute gout flares are treated with various agents, including nonsteroidal anti-inflammatory drugs, colchicine, glucocorticoids, and-more recently-IL-1 inhibitors. These medications can also be used as prophylaxis if urate-lowering therapy (ULT) is initiated. While these drugs can be used in patients with gout and CKD, there are often factors that complicate treatment, such as the numerous medication interactions involving colchicine and the effect of glucocorticoids on common comorbidities, such as diabetes and hypertension. ULT is recommended to treat recurrent flares, tophaceous deposits, and patients with moderate-to-severe CKD with a serum urate goal of <6 mg/dl recommended to prevent flares. While many misconceptions exist around the risks of using urate-lowering agents in patients with CKD, there is some evidence that these medications can be used safely in Patients with renal impairment. Additional questions exist as to whether gout treatment is indicated for Patients on RRT. Furthermore, there are conflicting data on whether ULT can affect renal function and cardiovascular disease in patients. All of these factors contribute to the unique challenges physicians face when treating patients with gout and CKD.
痛风是一种常见的炎症性关节炎,其特征是单钠尿酸盐晶体在关节和关节周围组织中的沉积。痛风反复发作会导致关节损伤,同时也会导致大量医疗保健资源的利用和生活质量的下降。患有 CKD 的患者痛风的患病率更高。由于缺乏质量数据来指导这一特定人群的管理,因此治疗患有 CKD 和痛风的患者具有挑战性。这往往导致痛风和肾功能受损患者的治疗效果不佳,因为对现有痛风治疗方法在这一人群中的疗效和安全性的担忧,常常导致治疗方案和剂量在不同医生之间存在显著差异。急性痛风发作可采用多种药物治疗,包括非甾体抗炎药、秋水仙碱、糖皮质激素,以及最近的 IL-1 抑制剂。如果开始使用尿酸降低治疗(ULT),这些药物也可以用作预防。虽然这些药物可用于痛风和 CKD 患者,但治疗通常会受到多种因素的影响,例如秋水仙碱涉及的许多药物相互作用,以及糖皮质激素对常见合并症(如糖尿病和高血压)的影响。ULT 推荐用于治疗复发性痛风发作、痛风石沉积和中重度 CKD 患者,建议血清尿酸目标值<6mg/dl 以预防发作。虽然人们对 CKD 患者使用尿酸降低药物存在许多误解,但有一些证据表明这些药物可以在肾功能受损的患者中安全使用。此外,还存在一些问题,即 RRT 患者是否需要进行痛风治疗。此外,关于 ULT 是否会影响患者的肾功能和心血管疾病,也存在相互矛盾的数据。所有这些因素都增加了医生在治疗痛风和 CKD 患者时所面临的独特挑战。